Jaguar Health (JAGX) received notice from the U.S. Food and Drug Administration’s Center for Veterinary Medicine of a $250,000 grant. Canalevia, under the name Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea in dogs. The grant would support a confirmatory study required for full FDA approval of Canalevia for the treatment of CID in dogs. Acceptance of the award is dependent upon the company’s compliance with FDA terms and conditions. The company has not yet accepted the award.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Animal Health Completes Private Placement of Preferred Stock
- Jaguar Animal Health Earnings Call: Growth Amid Challenges
- Jaguar Health to participate in 2025 Animal Health Summit
- Jaguar Health Announces Promising Trial Results
- Jaguar Health’s Napo to meet with FDA on pathways for croflemer in MVID